Marcos Isamat

Dr. Marcos Isamat

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LALucía Aragón-Serrano
Lucía Aragón-Serrano
LCLaura Carrillo-Serradell
Laura Carrillo-Serradell
VRVioleta Planells Romeo
Violeta Planells Romeo
MIMarcos Isamat
Marcos Isamat
MAMaría Velasco-de Andrés
María Velasco-de Andrés
LFLozano Francisco
Lozano Francisco
Cancer management still requires more potent and safer treatments, of which immunomodulatory receptors on the lymphocyte surface have started to show promise in new cancer immunotherapies (e.g., CTLA-4 and PD-1). CD6 is a signal-transducing transmembrane receptor, mainly expressed by all T cells and some B and NK cell subsets, whose endogenous ligands (CD166/ALCAM, CD318/CDCP-1, Galectins 1 and 3) are overexpressed by malignant cells of different lineages. This places CD6 as a potential target for novel therapies against haematological and non-haematological malignancies. Recent experimental evidence for the role of CD6 in cancer immunotherapies is summarised in this review, dealing with diverse and innovative strategies from the classical use of monoclonal antibodies to soluble recombinant decoys or the adoptive transfer of immune cells engineered with chimeric antigen receptors.

Verified
Journal Article
Open access
PDF file
LCLaura Carrillo-Serradell
Laura Carrillo-Serradell
JLJade Liu-Tindall
Jade Liu-Tindall
VRVioleta Planells Romeo
Violeta Planells Romeo
LALucía Aragón-Serrano
Lucía Aragón-Serrano
MIMarcos Isamat
Marcos Isamat
MAMaría Velasco-de Andrés
María Velasco-de Andrés
The fungal component of microbiota, known as the mycobiome, inhabits different body niches such as the skin and the gastrointestinal, respiratory, and genitourinary tracts. Much information has been gained on the bacterial component of the human microbiota, but the mycobiome has remained somewhat elusive due to its sparsity, variability, susceptibility to environmental factors (e.g., early life colonization, diet, or pharmacological treatments), and the specific in vitro culture challenges. Functionally, the mycobiome is known to play a role in modulating innate and adaptive immune responses by interacting with microorganisms and immune cells. The latter elicits anti-fungal responses via the recognition of specific fungal cell-wall components (e.g., β-1,3-glucan, mannan, and chitin) by immune system receptors. These receptors then regulate the activation and differentiation of many innate and adaptive immune cells including mucocutaneous cell barriers, macrophages, neutrophils, dendritic cells, natural killer cells, innate-like lymphoid cells, and T and B lymphocytes. Mycobiome disruptions have been correlated with various diseases affecting mostly the brain, lungs, liver and pancreas. This work reviews our current knowledge on the mycobiome, focusing on its composition, research challenges, conditioning factors, interactions with the bacteriome and the immune system, and the known mycobiome alterations associated with disease.

6 February 2023 in European Journal of Immunology
Verified
Journal Article
Open access
MAMaría Velasco-de Andrés
María Velasco-de Andrés
GMGuillermo muñoz
Guillermo muñoz
LCLaura Carrillo‐Serradell
Laura Carrillo‐Serradell
MGMaría del Mar Gutiérrez‐Hernández
María del Mar Gutiérrez‐Hernández
CCCristina Català
Cristina Català
LFLozano Francisco
Lozano Francisco
Adoptive cell transfer (ACT) therapies have gained renewed interest in the field of immunotherapy following the advent of chimeric antigen receptor (CAR) technology. This immunological breakthrough requires immune cell engineering with an artificial surface protein receptor for antigen‐specific recognition coupled to an intracellular protein domain for cell activating functions. CAR‐based ACT has successfully solved some hematological malignancies, and it is expected that other tumors may soon benefit from this approach. However, the potential of CAR technology is such that other immune‐mediated disorders are beginning to profit from it. This review will focus on CAR‐based ACT therapeutic areas other than oncology such as infection, allergy, autoimmunity, transplantation, and fibrotic repair. Herein, we discuss the results and limitations of preclinical and clinical studies in that regard.